Ignite Creation Date:
2024-05-06 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04683445
Status:
UNKNOWN
Last Update Posted:
2020-12-24
First Post:
2020-12-19
Brief Title:
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Overview
Official Title:
A Real-world Study Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2020-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chemotherapy is an important means to prolong the survival time of advanced breast cancer As a new type of microtubule inhibitor eribulin has a unique mechanism of action Compared with single drug chemotherapy it can improve the overall survival time of 25 months increase the clinical benefit rate by 5 times and the tolerance of eribulin is good Therefore the guidelines at home and abroad recommend eribulin for the rescue of advanced breast cancer
However up to now there is no large sample data on the efficacy of eribulin combined with anti HER2 targeted therapy in HER2 metastatic breast cancer and the efficacy of combined immunotherapy in triple negative metastatic breast cancer Moreover as a newly marketed chemotherapy drug in China the efficacy and safety data of eribulin in Chinese population are relatively lacking Therefore we plan to include different types and line numbers of advanced breast cancer patients based on the Chinese population through real-world research and receive the treatment regimen containing eribulin respectively In HR her2-mbc we use eribulin monotherapy in HER2 MBC we use eribulin anti HER2 targeted therapy in TNBC we use eribulin immunotherapy chemotherapy The efficacy and safety of eribulin were evaluated
However up to now there is no large sample data on the efficacy of eribulin combined with anti HER2 targeted therapy in HER2 metastatic breast cancer and the efficacy of combined immunotherapy in triple negative metastatic breast cancer Moreover as a newly marketed chemotherapy drug in China the efficacy and safety data of eribulin in Chinese population are relatively lacking Therefore we plan to include different types and line numbers of advanced breast cancer patients based on the Chinese population through real-world research and receive the treatment regimen containing eribulin respectively In HR her2-mbc we use eribulin monotherapy in HER2 MBC we use eribulin anti HER2 targeted therapy in TNBC we use eribulin immunotherapy chemotherapy The efficacy and safety of eribulin were evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None